RBC Capital Lowers Alnylam Pharmaceuticals PT to $465, Maintains Outperform Rating.

martes, 20 de enero de 2026, 11:02 am ET1 min de lectura
ALNY--

RBC Capital Lowers Alnylam Pharmaceuticals PT to $465, Maintains Outperform Rating.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios